Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Net Income (2017 - 2025)

Historic Net Income for Dianthus Therapeutics (DNTH) over the last 8 years, with Q3 2025 value amounting to -$36.6 million.

  • Dianthus Therapeutics' Net Income fell 4390.1% to -$36.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$125.5 million, marking a year-over-year decrease of 8702.54%. This contributed to the annual value of -$84.5 million for FY2024, which is 9465.33% down from last year.
  • Dianthus Therapeutics' Net Income amounted to -$36.6 million in Q3 2025, which was down 4390.1% from -$31.5 million recorded in Q2 2025.
  • In the past 5 years, Dianthus Therapeutics' Net Income ranged from a high of -$7.1 million in Q1 2023 and a low of -$36.6 million during Q3 2025
  • In the last 4 years, Dianthus Therapeutics' Net Income had a median value of -$14.7 million in 2023 and averaged -$18.7 million.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 456.58% in 2023, then plummeted by 16565.83% in 2024.
  • Over the past 4 years, Dianthus Therapeutics' Net Income (Quarter) stood at -$10.1 million in 2022, then dropped by 4.57% to -$10.5 million in 2023, then tumbled by 165.66% to -$27.9 million in 2024, then tumbled by 31.17% to -$36.6 million in 2025.
  • Its Net Income was -$36.6 million in Q3 2025, compared to -$31.5 million in Q2 2025 and -$29.4 million in Q1 2025.